Cello Group plc’s (CLL) Buy Rating Reaffirmed at FinnCap
A number of other equities analysts have also recently issued reports on the company. Peel Hunt restated a buy rating and set a GBX 130 ($1.62) price target on shares of Cello Group plc in a report on Wednesday, October 19th. N+1 Singer restated a buy rating and set a GBX 128 ($1.60) price target (up from GBX 127 ($1.59)) on shares of Cello Group plc in a report on Tuesday, September 20th. Finally, Cenkos Securities Ltd restated a buy rating on shares of Cello Group plc in a report on Wednesday, September 14th. Five equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and a consensus price target of GBX 123.75 ($1.55).
Shares of Cello Group plc (LON:CLL) traded up 0.644% during trading on Thursday, reaching GBX 97.625. 1,000 shares of the company were exchanged. Cello Group plc has a one year low of GBX 77.10 and a one year high of GBX 115.00. The company’s market capitalization is GBX 84.75 million. The firm’s 50 day moving average price is GBX 101.76 and its 200 day moving average price is GBX 100.31.
The firm also recently announced a dividend, which was paid on Friday, November 4th. Stockholders of record on Thursday, October 6th were given a dividend of GBX 1 ($0.01) per share. This represents a dividend yield of 0.94%. The ex-dividend date was Thursday, October 6th.
About Cello Group plc
Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.
Receive News & Stock Ratings for Cello Group plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Group plc and related stocks with our FREE daily email newsletter.